Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma

Yamamoto, Kazuhiro; Yano, Ikuko

doi:10.1007/s12032-017-1077-0

Cited by 11 publications

(7 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a larger subset of patients with mutated TP53 and KRAS as well as wt- BRAF , treatment with Cetuximab was associated with an increase in PFS [ 96 ]. Similar results were seen with the use of Panitumumab in patients with tumor p53 mutations, who showed a better PFS than those without such mutations [ 97 ]. Therefore, analyzing p53 in extension to KRAS / BRAF status may identify new subpopulations that could benefit from anti-EGFR treatment—perhaps also independently of tumor site (right-sided vs. left-sided).…”

Section: Treatment Response To Systemic Therapysupporting

confidence: 72%

The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

Michel

Kaps

Maderer

et al. 2021

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common and fatal cancers worldwide. The carcinogenesis of CRC is based on a stepwise accumulation of mutations, leading either to an activation of oncogenes or a deactivation of suppressor genes. The loss of genetic stability triggers activation of proto-oncogenes (e.g., KRAS) and inactivation of tumor suppression genes, namely TP53 and APC, which together drive the transition from adenoma to adenocarcinoma. On the one hand, p53 mutations confer resistance to classical chemotherapy but, on the other hand, they open the door for immunotherapy, as p53-mutated tumors are rich in neoantigens. Aberrant function of the TP53 gene product, p53, also affects stromal and non-stromal cells in the tumor microenvironment. Cancer-associated fibroblasts together with other immunosuppressive cells become valuable assets for the tumor by p53-mediated tumor signaling. In this review, we address the manifold implications of p53 mutations in CRC regarding therapy, treatment response and personalized medicine.

show abstract

Section: Treatment Response To Systemic Therapysupporting

confidence: 72%

The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

Michel

Kaps

Maderer

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…This finding raises a critical question of identification of the factors determining which patients are more likely to respond to treatment. Genetic factors have been shown to impact the efficacy of many therapies for various diseases [Berinstein and Levy, 2017, Matera et al, 2017, Politi et al, 2018, Yamamoto and Yano, 2018], and provide the basis for the development of “personalized medicine” [Di Paolo et al, 2017, Kent et al, 2018, Zhou et al, 2018]. Our results support the necessity of further research into the possibility of introducing personalized medicine into pain management.…”

Section: Discussionsupporting

confidence: 68%

Efficacy of acetaminophen versus ibuprofen for the management of rotator cuff-related shoulder pain: Randomized open-label study

AlRuthia

Alghadeer

Balkhi

et al. 2019

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

BackgroundShoulder pain related to the rotator cuff (RC) is one of the most common and bothersome musculoskeletal complaints. Pharmacologic treatment most often includes acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. However, data allowing comparison of the efficacy of these two drugs are very limited. We compared the therapeutic outcomes of acetaminophen and ibuprofen in the management of RC-related pain.MethodsThis was an open-label, two-center, active-control, prospective randomized clinical trial. Participants were assigned randomly to acetaminophen or ibuprofen treatment groups. The acetaminophen dose was 500 mg every 6–8 h, and it was 400–800 mg every 6–8 h for ibuprofen. The impact of the treatment was measured by Shoulder Pain and Disability Index (SPADI), Quick Disabilities of the Arm, Shoulder, and Hand (Quick-DASH) and World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and after 6 weeks of therapy.ResultsThirty-three patients completed the study; 20 treated with ibuprofen and 13 with acetaminophen. Patients in both groups were comparable at baseline with regard to SPADI, Quick-DASH, and WHOQOL-BREF scores. After 6 weeks of treatment, patients receiving ibuprofen, but not acetaminophen, reported an improvement in pain severity and functional activity (as measured by SPADI and Quick-DASH). Patients taking acetaminophen, but not ibuprofen, reported improvement in the physical and environmental domains of WHOQOL-BREF scores.ConclusionsIbuprofen and acetaminophen provide benefits to patients suffering from RC-related pain. However, the type of improvement perceived by patients differed between these two medications.

show abstract

“…Some studies in adults demonstrated that suffering from multiple diseases is a risk factor for SADRs ( 26 ), and might correlate with the decrease in drug metabolism or the damage to liver and kidney functions. Interaction among diseases might result in poor physical, emotional and social functions ( 27 ). However, in our study, children with multiple disease did not show significant differences in ADR severity.…”

Section: Discussionmentioning

confidence: 99%

Suspected Adverse Drug Reactions in Pediatric Cancer Patients in China: An Analysis of Henan Province Spontaneous Reporting System Database

et al. 2021

View full text Add to dashboard Cite

IntroductionAdverse drug reactions (ADRs) in pediatric cancer patients have not yet received due attention in the world. Antineoplastic drugs are frequently related to ADRs. Few studies focus on the ADR and the intervention measures in pediatric cancer patients.MethodsADR reports submitted to Henan Adverse Drug Reaction Monitoring Center from 2016 to 2020 for individuals aged from birth to 17 years (including 17 years) were included. Data were analyzed with respect to gender, age, disease types, past history of ADR, occurrence time of ADR, polypharmacy, route of administration, off-label drug use, name of suspected drugs per ADR report, and severity of ADR reports.ResultsA total of 431 ADR reports related to antineoplastic drugs in pediatric patients were collected, 31.55% were serious ADRs (SADRs). The median age of patients was six years (inter quartile range, IQR: 3-11), the age groups with higher reporting rates were concentrated in 1-3-year-olds (130). Past history of ADR, occurrence time of ADR and polypharmacy were statistically associated with SADR. Myelosuppression was the most frequent ADR (15.55%), cytarabine was the most frequent drug (26.22%). The signal mining method produced 14 signals, three signals were off-label ADRs.ConclusionsThis study described the characteristics of ADRs in pediatric cancer patients. By conducting signal mining method, three off-label ADRs need further study. We should pay more attention to these ADRs and develop relative management strategies. More researches are needed to achieve a better understanding of the characteristics of ADRs in pediatric cancer patients of China.

show abstract

Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma

Cited by 11 publications

References 99 publications

The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

Efficacy of acetaminophen versus ibuprofen for the management of rotator cuff-related shoulder pain: Randomized open-label study

Suspected Adverse Drug Reactions in Pediatric Cancer Patients in China: An Analysis of Henan Province Spontaneous Reporting System Database

Contact Info

Product

Resources

About